China Remains at Risk to Future MonkeyPox Outbreaks.

GeoVax (GOVX) intends to become the first U.S.-based supplier of the MVA vaccine to prevent Mpox and smallpox.

GeoVax Live Webcast

Tonight, Monday at 5:30 PM. And You Don't Fly to Newport Beach and Deal With all the Drinking, Investment Bankers, and...

U.S. Population Classified as ‘Immunocompromised’ Explodes Higher, in Latest JAMA Report.

New report nearly doubles the GeoVax addressable market of Immunocompromised Patients (i.e. potential customers) from 15 Million, to 23 Million patients! Not...

The Extraordinary Dr. Koffman, Who Beat Leukemia.

Dr. Brian Koffman is extraordinary, in many ways. He’s extraordinary in the medical sense because, after twelve years of battling blood...

GeoVax (GOVX) Conference Call at 4:30 ET, the 29th.

GeoVax to Host Conference Call at 4:30 PM ET GeoVax to Report 2023 Financial Results and Provide Corporate...

Dalrada (DFCO). Our 11th and Latest Ten Bagger.

We've actually had many more than 11 ten-baggers, as we report on companies which aren't clients. This is our 11th client we...

GeoVax to Present at the 2024 BIO CEO & Investor Conference

ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers...

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!

Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants We were having cocktails at...

GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.

(Presentation text bolding for emphasis by Editors of the Biotech Stock Review, not the company.

Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.

Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for...

Latest article

Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!

When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...

GeoVax to Provide Corporate Update on Tuesday May 14, 2024.

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...

NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...